CME Objectives | Statement of Need and Purpose | Accreditation Statement | Credit Designation | Date of Original Release/Review | Faculty | Faculty Disclosure | Disclosure of Off-Label Usage | Acknowledgment | Drug Names

This activity uses portable document files (PDFs) and Macromedia Flash 5 files. For more information about these formats, visit our online media page.

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME). To obtain credit, please study the activity material and complete the posttest as instructed.

CME Objectives

After completing this educational activity, participants should be able to:

• List several reasons why patients stop antidepressant treatment
• Describe several strategies to improve compliance with antidepressant treatment

Statement of Need and Purpose

Noncompliance with treatment occurs in up to 60% of antidepressant-treated patients. This activity was designed to meet the needs of participants in the Physicians Postgraduate Press CME activities who have requested information on improving compliance in their antidepressant-treated patients. There are no prerequisites for this activity.

Accreditation Statement

Physicians Postgraduate Press, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physicians Postgraduate Press, Inc. designates this educational activity for up to 2 hours of Category 1 credit toward the AMA Physician’s Recognition Award. Each participant should claim only those hours of credit that he/she actually spent in the educational activity.

Date of Original Release/Review

This Online Insight was published in May 2002. This activity is eligible for CME credit through May 31, 2003. The latest review of this material was February 2002.

Faculty

Chair, David J. Kupfer, M.D., Western Psychiatric Institute and Clinic, Pittsburgh, Pa.

Timothy G. Dinan, M.D., Ph.D., University College, Cork, Ireland

David L. Dunner, M.D., University of Washington, Seattle

Maurizio Fava, M.D., Massachusetts General Hospital, Boston

Faculty Disclosure

In the spirit of full disclosure and in compliance with all ACCME Essential Areas and Policies, the faculty for this continuing medical education activity were asked to complete a full disclosure statement. The information received is as follows:

Dr. Kupfer is a member of the speakers’/advisory board for Pfizer, Lilly, and Forest.

Dr. Dinan has received honoraria from and is a member of the speakers’/advisory board for Lilly, Pfizer, Lundbeck, and Organon.

Dr. Dunner is a consultant for Lilly, Wyeth-Ayerst, GlaxoSmithKline, Bristol-Myers, and Novartis; has received research grant support from Pfizer, Wyeth-Ayerst, Pharmacia & Upjohn, and Cyberonics; and has received honoraria from Lilly, GlaxoSmithKline, Bristol-Myers, and Wyeth.

Dr. Fava has received research grant support and honoraria from Lilly, SmithKline, Pfizer, Wyeth-Ayerst, Organon, Bristol-Myers, Pharmacia & Upjohn, Glaxo, Solvay, Forest, Sanofi, and Synthelabo; has received honoraria from Janssen, Lundbeck, Knoll, Parke-Davis, Somerset, and Pharmavite; and has received research grant support from Abbott, Roche, Novartis, Lorex, and Litchwer Pharma GmbH.

Disclosure of Off-Label Usage

In this Online Insight, faculty may be presenting investigational information about pharmaceutical agents that is outside of U.S. Food and Drug Administration–approved labeling. This information is intended solely as continuing medical education and is not intended to promote off-label use of any of these medications. To the best of his knowledge, Dr. Kupfer has determined that citalopram, desipramine, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine are not approved by the U.S. Food and Drug Administration for the treatment of recurrent depression. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

Acknowledgment

The discussion contained in this Online Insight activity was taken from the teleconference “Treatment Recommendations Versus Treatment Realities: Their Effect on Compliance and Persistence in Patients With Depression,” held December 21, 2001. The teleconference and this Online Insight activity were independently developed by the Physicians Postgraduate Press, Inc. Office of Continuing Medical Education pursuant to an unrestricted educational grant from Eli Lilly and Company. The opinions expressed herein are those of the authors and do not necessarily reflect the views of the publisher and CME provider or the commercial supporter.

Drug Names

citalopram (Celexa), desipramine (Norpramin and others), fluoxetine (Prozac and others), nefazodone (Serzone), paroxetine (Paxil), sertraline (Zoloft), venlafaxine (Effexor)